IVI in the Media
South China Morning Post | The latest coronavirus boosters target Omicron. Are they safe and effective?
Financial News | IVI Director General Jerome Kim: ‘Bill Gates a strong advocate of IVI’
South China Morning Post | Scientists urge people to take second Covid vaccine booster if offered as Omicron continues to spread
Financial Times | Unvaccinated and unprepared, North Korea faces Covid catastrophe
Chosun Ilbo | Jerome Kim, Director General of International Vaccine Institute, named a distinguished professor at Seoul National University
Financial Times | South Korea downgrades Covid to a ‘Class 2’ disease and removes restrictions
South China Morning Post | China was the world’s biggest Covid-19 vaccine exporter. Not any more
The Wall Street Journal | Despite High Covid-19 Case Counts, Asian Nations Learn to Live With the Virus
Barron’s | China Eases Some Covid Testing Rules. It’s a Targeted Approach to Reduce Impact on the Economy.
CNBC | We need to treat Covid as an endemic pathogen and update vaccines: International Vaccine Institute
Financial Times | Beijing digs in to avoid repeating Hong Kong’s Covid mistakes
The Telegraph | Why China and Hong Kong face a devastating new Covid wave
CGTN | Why is China seeing a surge in COVID-19 cases?
Financial Times | Shanghai teeters on the brink of Covid lockdown
ADB Insight | Year of the Vaccine: The Next Steps for Asia and the Pacific to Combat COVID-19
Fortune | Will we all need fourth COVID vaccine booster shots?
The Telegraph | South Korea abandons its successful test and trace system as omicron cases surge
South China Morning Post | Can China’s home-grown mRNA Covid-19 vaccine pass its final tests?
The Guardian | Cuba leads the world in vaccinating children as young as two against Covid
The Telegraph | Vaccine hesitancy among Taiwan’s elderly mars its pandemic performance and prevents reopening
Director General Jerome Kim on The Alex Salmond Show
South China Morning Post | Which vaccines stop Omicron? Search for data moves from labs to real world
CNBC | 2022 will be the ‘year of vaccination,’ says director of vaccine institute
South China Morning Post | As Omicron upends Covid-19 vaccine targets, what will the future look like?
South China Morning Post | Omicron and the Winter Olympics – is China’s zero-Covid strategy up to the challenges?
CBS Mornings | With Omicron on its doorstep, countries in Asia are closing up
National Geographic | Omicron is dodging the immune system—but boosters show promising signs
Khaleej Times | Covid: 96% of people in low-income nations have yet to receive first vaccine dose, says expert
Voice of America | South Korea Showed How to Contain COVID, Now It Will Try to Live With It
China Daily | Experts say countries should remain cautious about reopening borders
South China Morning Post | Next Covid-19 test? Diagnostic blind spots stir visions of bleak midwinter
South China Morning Post | US-China coronavirus vaccine diplomacy heats up but can donations sway allegiances?
The New York Times | How Asia, Once a Vaccination Laggard, Is Revving Up Inoculations
South China Morning Post | Coronavirus: as rich countries turn to big-name booster shots from Pfizer, AstraZeneca, the poor are left with lesser-known rivals like Abdala, Soberana 2
South China Morning Post | Coronavirus: China seeks to develop next-gen vaccines amid trial complications
South China Morning Post | Can China stay ahead as a leading exporter of Covid-19 vaccines?
Maeil Business Newspaper | All music is beautiful in its own way, but Violinist Sang Hee Lee’s music shines a special light
Nature | Six months of COVID vaccines: what 1.7 billion doses have taught scientists
Asian Boss | We Asked Top Vaccine Expert About COVID Vaccine Problems
Bloomberg | Consequences of ‘Huge’ Global Gap in Vaccinations
EIU Perspectives | What does Denmark’s permanent suspension of both the AstraZeneca and Janssen covid-19 vaccines mean for other countries?
Asia Times | Vaccinations in a race against viral variants
Nature | Why COVID vaccines are so difficult to compare
DEVEX | Opinion: COVAX — too big, and too important, to fail
CNN | “Our response needs to be clear, strong, and unified”
South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think
Bloomberg | Will the Covid-19 Vaccines Be Effective and Safe?
Asian Boss | Update On COVID-19 Vaccine Price & Schedule From A Leading Vaccine Expert
The Telegraph | ‘If you are not prepared, the virus has found every weakness’: How countries in Asia tamed Covid-19
CGTN | ‘The vaccine itself is not the silver bullet,’ says International Vaccine Institute
Devex | Q&A: Why Jerome Kim is ‘hopeful’ but cautious about distributing a COVID-19 vaccine
Maeil Business Newspaper | IVI Director General Jerome Kim Shares His Thoughts on Resurgence of COVID-19 Outbreaks in S. Korea
Chosun Ilbo | IVI Director General Jerome Kim Shares His Thoughts on Equitable Access of COVID-19 Vaccines
Channel News Asia | On a fast track like never before: The COVID-19 vaccine effort and 5 vital questions
The Economist’s Future of Healthcare Insight Hour | Vaccine development: A race to the finish line
Devex | Q&A: Is COVID-19 helping or hindering progress toward an HIV vaccine?
TED | The trials, tribulations and timeline of a COVID-19 vaccine
Wired Korea | The End of World War C: Peace without Victory?
Asian Boss | World’s Leading Vaccine Expert Fact-Checks COVID-19 Vaccine Conspiracy
Development Today | Why Sweden funds a vaccine institute in Korea and not Oslo-based CEPI
CNBC | Parts of Asia that relaxed restrictions without a resurgence in coronavirus cases did these three things
The Korea Herald | [Herald Interview] ‘Making vaccines accessible is biggest COVID-19 challenge’
CGTN: The Agenda with Stephen Cole | Speed of vaccine trials is ‘unprecedented’
Asian Boss | We Asked The World’s Leading Vaccine Expert About COVID-19 Vaccine
The Guardian | Test, trace, contain: how South Korea flattened its coronavirus curve
BBC World Service: The Inquiry | How do we come out of the lockdown? (13:00)
ANC 24/7 | Int’l Vaccine Institute: 12-18 months reasonable timetable for development of Covid-19 vaccine
Seeker | How Fast Can We Make a Coronavirus Vaccine?
Education City Speaker Series: Flattening the Curve – Global Responses to COVID-19
Wion News | About 70% of vaccines used around the world are made in India: S Korean expert Dr Jerome Kim
South China Morning Post | How long will a coronavirus vaccine take? A Q&A with Jerome Kim, head of the International Vaccine Institute
BBC World News | Jerome Kim: Vaccines are the long-term solution to the pandemic
The Korea Times | Developing vaccine against COVID-19
TRT: Bigger than Five | COVID-19: The World Reacts
South Korea’s fight against coronavirus (CBS News)
NDTV | Top South Korea Doctor On Why He Thinks Coronavirus Is Not A ‘Chinese Virus’
RTE | What South Korea can teach Ireland about fighting Covid-19
Physical distancing should last months, not weeks, says epidemiologist (Yahoo News Canada)
Development of vaccine requires massive investment… international cooperation is needed (Korea Economic Daily)
COVID-19 Pandemic (Arirang TV, 22:50~46:00)
By then, we’ll have a vaccine on our side (Hankyoreh—Korean)
Coronavirus Pandemic: International Vaccine Institute director on how long it will take to develop vaccine (CGTN)
Testing times: Why South Korea’s COVID-19 strategy is working (Al Jazeera English)
Genexine seeks to compress the vaccine timeline
Genexine, Binex to develop COVID-19 vaccine (Korea Biomedical Review)
Genexine, Binex to co-develop coronavirus vaccine GX-19 (Korea Herald)
How close are we to a COVID-19 vaccine? Jerome H. Kim from International Vaccine Institute (Arirang News)
COVID-19 vaccine, drugs on fast track for development: IVI chief (Yonhap News)
Inside the race to find a coronavirus vaccine (Devex)
Chinese students keen for turnaround (China Daily)
China Daily | S. Korea can try out makeshift hospitals, experts say
Director General Jerome Kim for Phoenix TV
Speed and accuracy vital for COVID-19 test kits (Arirang News)
2020 COVID-19 Live Updates: Jerome Kim for tbs eFM
Jerome Kim for KBS WORLD Radio, Korea24 on the COVID-19 outbreak in South Korea
Korea should join efforts in vaccine development to prevent pandemics (JoongAng Ilbo)
Future global health threats
IVI: COVID-19 could linger (Korean)
Jerome Kim for Korea, Factual: “Hong Kong’s handling of COVID-19 outbreak & Prospects of vaccine development”
Concerns about the spread of COVID-19: When will a vaccine be developed? When can we expect the “Super Vaccine”?
Al Jazeera English | Scientists call for global cooperation over coronavirus
When will COVID-19 vaccine be commercialized…And “super vaccine”? (Korean)
Global push to find vaccine against devastating bug growing
IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine
Korean vaccines expanding global territory
Neglected Victims of Neglected Diseases
Let’s build a common defense against epidemics
Vaccine investment brings 16-fold return… partnering with Bill Gates
World must join forces to prevent infectious diseases
IVI editorial in The Korea Herald advocates for Korean leadership for global health
×
160 000 people targeted with oral cholera vaccine in Nsanje
Wednesday, 25 March 2015 18:42
160 000 people targeted with oral cholera vaccine in Nsanje
Written by Martin Chiwanda
Oral cholera vaccine
Nsanje, March 25: The Ministry of Health is expected to embark on an Oral Cholera Vaccine campaign targeting 160,000 people in the flood hit Nsanje district.
Ministry of Health Epidemiologist Settie Kanyanda disclosed the development in an interview Tuesday on the sidelines of a District Executive Committee meeting in Nsanje.
He said the ministry had targeted Nsanje because it was prone to the cholera outbreak.
“Nsanje district is experiencing more cases of cholera as compared to other districts. We feel that the Oral vaccine is a preventive measure to the attacks," he stated.
Kanyada assured communities in Nsanje that the vaccine would make a difference in the fight against cholera as it works for five years.
“The Shanchol vaccine which will be given in two doses with interval between 2 to 6 weeks is one of the oral cholera vaccine prequalified by World Health Organisation (WHO) in September 2011 for use by member countries. It is a bivalent whole cell killed oral cholera vaccine with an efficacy of 65percent for five years,” he explained.
With the limited resources available to the ministry, Kanyanda said the exercise will only be administered in Nsanje targeting 160, 000 people which is half the district's population projected at 280, 000.
“The vaccine will be administered to all 100, 000 to 160, 000 people in the district with ages from one year and above living in camps and surrounding communities. We cannot afford to provide the vaccine to the whole population because of limited resources."
“This exercise has been supported by the World Health Organization and the International Vaccine Institute of Korea. However, we are appealing to other partners to come in and assist in the course,” added Kanyanda.
He also challenged people in the lower shire district to continue exercising good hygiene practices if they were to be safe from typhoid and other diarrhea diseases.
“World Health Organization recommends that vaccination should be used as a tool to control cholera however provision of clean water and adequate sanitation remain the mainstays of cholera control,” clarified Kanyanda.
As of Monday, 23rd March, 2015, Nsanje district had recorded 137 cases of cholera with two deaths, according to District Medical Officer, Dr. Yamikani Mastala.
The Oral vaccine exercise first dose will commences on March 31 and ends on April 4, 2014.